iSpecimen Inc. (ISPC) SEC filings

ISPCNasdaqServices-Commercial Physical & Biological ResearchFiscal year ends December 31

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026Score 7/3028% below fair value

$0.71−0.03 (-3.81%)

Close on Nov 11, 2026Market cap $1.79MP/E –Yield –

SEC filings

40 of iSpecimen's most recent filings on SEC EDGAR

Document	Form	Period	Filed	Source
Current report	8-K	Nov 5, 2026	Nov 9, 2026	SEC EDGAR
Current report	8-K	Nov 2, 2026	Nov 5, 2026	SEC EDGAR
Current report	8-K	Oct 30, 2026	Nov 2, 2026	SEC EDGAR
Current report	8-K	Oct 9, 2026	Oct 9, 2026	SEC EDGAR
Proxy statement	DEF 14A	Oct 9, 2026	Sep 14, 2026	SEC EDGAR
Current report	8-K	Sep 8, 2026	Sep 10, 2026	SEC EDGAR
Current report	8-K	Sep 4, 2026	Sep 4, 2026	SEC EDGAR
Current report	8-K	Aug 26, 2026	Aug 31, 2026	SEC EDGAR
Current report	8-K	Aug 12, 2026	Aug 14, 2026	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2026	Aug 14, 2026	SEC EDGAR
Current report	8-K	Aug 6, 2026	Aug 11, 2026	SEC EDGAR
Current report	8-K	Aug 5, 2026	Aug 7, 2026	SEC EDGAR
Current report	8-K	Jul 9, 2026	Jul 14, 2026	SEC EDGAR
Current report	8-K	May 29, 2026	Jun 1, 2026	SEC EDGAR
Current report	8-K	May 29, 2026	May 29, 2026	SEC EDGAR
Quarterly report	10-Q	Mar 31, 2026	May 18, 2026	SEC EDGAR
Current report	8-K	May 8, 2026	May 13, 2026	SEC EDGAR
Current report	8-K	Apr 29, 2026	May 1, 2026	SEC EDGAR
Current report	8-K	Apr 10, 2026	Apr 13, 2026	SEC EDGAR
Current report	8-K	Apr 9, 2026	Apr 10, 2026	SEC EDGAR
Annual report	10-K	Dec 31, 2025	Apr 1, 2026	SEC EDGAR
Current report	8-K	Mar 13, 2026	Mar 13, 2026	SEC EDGAR
Current report	8-K	Feb 17, 2026	Feb 23, 2026	SEC EDGAR
Current report	8-K	Feb 13, 2026	Feb 18, 2026	SEC EDGAR
Current report	8-K	Feb 6, 2026	Feb 6, 2026	SEC EDGAR
Current report	8-K	Jan 23, 2026	Jan 27, 2026	SEC EDGAR
Current report	8-K	Dec 31, 2025	Jan 5, 2026	SEC EDGAR
Current report	8-K	Dec 31, 2025	Jan 5, 2026	SEC EDGAR
Current report	8-K	Dec 30, 2025	Jan 2, 2026	SEC EDGAR
Current report	8-K	Nov 28, 2025	Dec 1, 2025	SEC EDGAR
Current report	8-K	Nov 19, 2025	Nov 21, 2025	SEC EDGAR
Proxy statement	DEF 14A	Dec 31, 2025	Nov 21, 2025	SEC EDGAR
Quarterly report	10-Q	Sep 30, 2025	Nov 17, 2025	SEC EDGAR
Current report	8-K	Nov 7, 2025	Nov 7, 2025	SEC EDGAR
Current report	8-K	Oct 30, 2025	Nov 3, 2025	SEC EDGAR
Proxy statement	DEF 14A	Oct 30, 2025	Oct 14, 2025	SEC EDGAR
Current report	8-K	Sep 4, 2025	Sep 4, 2025	SEC EDGAR
Current report	8-K	Aug 21, 2025	Aug 21, 2025	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2025	Aug 14, 2025	SEC EDGAR
Current report	8-K	Aug 7, 2025	Aug 7, 2025	SEC EDGAR

Where these numbers come from

Parsed from the XBRL in iSpecimen's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-40 reverse split on Apr 28, 2026
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is ISPC.

Compare: ISPC vs ONMD · ISPC vs ABSI · ISPC vs CBIH · ISPC vs MWAI · ISPC vs AIDX

Revenue growth-92.1% · median -47.2%

Gross margin-98.0% · median 5.0%

Operating margin-2020.0% · median -695.7%

Net margin-2449.0% · median -584.2%

Company	Revenue	Growth
ABSI	$1.49M	-47.2%
ONMD	$1.46M	+216.5%
ISPC	$466.30K	-92.1%
CBIH	$123.63K	-64.1%
MWAI	–	–
AIDX	–	–

Company

Exchange: Nasdaq
Industry: Services-Commercial Physical & Biological Research
Fiscal year ends: December 31
Employees: 53
Held by institutions: 2.3%
Auditor: Bush & Associates CPA LLC
SEC CIK: 1558569

Advertisement
300 × 250

See a number that looks wrong?